Prot #CV0291001: A Phase 2A, Double-Blind, Randomized, Placebo-Controlled, MultiCenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants with HFpEF

Project: Research project

Project Details

StatusActive
Effective start/end date5/13/24 → 5/13/27

Funding

  • PPD Investigator Services, LLC (Prot #CV0291001 // Prot #CV0291001)
  • Bristol-Myers Squibb Company (Prot #CV0291001 // Prot #CV0291001)